// App-Quantinova.ai

900 : Abatacept Vs. Placebo in Early Diffuse Cutaneous Systemic Sclerosis— Results of a Phase 2 Investigator Initiated, Double-Blind, Placebo-Controlled, Multicenter, Randomized Controlled Trial Study

Researchers

Presenter

  • Cathie Spino

Principal Investigators

  • Sindhu Johnson

  • Lorinda Chung

  • Jerry Molitor

  • Virginia D. Steen

  • Robert Lafyatis

  • Robert W. Simms

  • Christopher P. Denton

  • Suzanne Kafaja

  • Tracy M. Frech

  • Vivien Hsu

  • Robyn T. Domsic

  • Janet E. Pope

  • Jessica K. Gordon

  • Maureen D. Mayes

  • Elena Schiopu

  • Amber Young

  • Nora Sandorfi

  • Jane Park

  • Faye N. Hant

  • Elana J. Bernstein

  • Soumya Chatterjee

  • Flavia V. Castelino

  • Ali Ajam

  • Yannick Allanore

  • Marco Matucci-Cerinic

  • Oliver Distler

  • Ora Singer

  • Haoyan Zhong

  • David Fox

  • Daniel E. Furst

Medical Centers

  • Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, United States.

  • Biostatistics Unit, University of Michigan, Ann Arbor, MI

  • University of Michigan, Ann Arbor, MI

  • Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada

  • Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, CA

  • Rheumatic & Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN

  • Neurology, Medstar Georgetown University Hospital, Washington DC, DC

  • Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA

  • Medical School, Boston University School of Medicine, Boston, MA

  • UCL Division of Medicine, Royal Free Campus, London, United Kingdom

  • Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA

  • Division of Hematology, The University of Utah, Salt Lake City, UT

  • Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ

  • Dept. Pathology, University of Pittsburgh, Pittsburgh, PA.

  • Department of Medicine, University of Western Ontario, London, ON, Canada

  • Division of Rheumatology, Hospital for Special Surgery, New York, NY

  • Rheumatology, University of Texas Medical School, Houston, TX

  • Perelman School of Medicine, University of Pennsylvania, Ardmore, PA

  • Seattle Rheumatology Associates, Seattle, WA

  • Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC

  • Pathology Columiba University, New York, NY

  • Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH

  • Pathology, Harvard Medical School, Boston, MA

  • Rheumatology & Immunology, The Ohio State University Wexner Medical Center, Columbus, OH

  • Service de Rhumatologie, Hopital Cochin, paris, France

  • Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

  • Department of Neurology, University Hospital Zurich, Zurich, Switzerland

  • Department of Internal Medicine, University of Michigan, Ann Arbor, MI

  • Department of Internal Medicine, University of Michigan, Ann Arbor, MI

  • UCLA, Los Angeles, CA

Locations

  • United States

  • Canada

  • United Kingdom

  • France

  • Italy

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Central Nervous System (CNS)

Disease

  • N/A

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Abatacept

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • II

Study Id's

  • NCT02161406

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved